NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB - LARVOL DELTA

NeuroEPO plus (NeuralCIM) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial. (PubMed, Alzheimers Res Ther) - "Among participants with mild-moderate Alzheimer's disease clinical syndrome, neuroEPO plus improved the cognitive evaluation at 48 weeks, with a very good safety profile. Larger trials are warranted to determine the efficacy and safety of neuroEPO plus in Alzheimer's disease."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Inflammation

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

NeuralCIM® in Neurodegenerative Disorders: a hope to travel the path of Alzheimer’s. (AAIC 2023) - "Background: NeuroEPO (NeuralCIM ® ) is a variant of EPO, which contains low sialic acid... NeuralCIM ® treatment, stabilized the progression of AD clinical syndrome, during two years of treatment."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

EEG as a mediator for the causal effect of NeuroEPO on motor performance and cognition in Parkinson (OHBM 2023) - "This study showed that the causal effect of NeuroEPO on cognitive and motor outcomes is mediated by qEEG(as a proxy of brain function). These results demonstrate the potential of qEEG as a tool for detecting the interventional effect of the drugs in PD patients."

Ataxia • CNS Disorders • Parkinson's Disease

EEG as a mediator for the causal effect of NeuroEPO on motor performance and cognition in Parkinson (OHBM 2023) - "This study showed that the causal effect of NeuroEPO on cognitive and motor outcomes is mediated by qEEG(as a proxy of brain function). These results demonstrate the potential of qEEG as a tool for detecting the interventional effect of the drugs in PD patients."

Ataxia • CNS Disorders • Parkinson's Disease

NEUROEPO IN NEURODEGENERATIVE DISORDERS (ADPD 2023) - "No serious adverse events related with NeuroEPO were reported. Conclusions NeuroEPO improved clinical outcomes with a good safety profile in patients with SCA2, PD and mild-to-moderate Alzheimer's clinical syndrome."

Alzheimer's Disease • Ataxia • CNS Disorders • Movement Disorders • Parkinson's Disease

Sensitive Analysis of Recombinant Human Erythropoietin Glycopeptides by On-Line Phenylboronic Acid Solid-Phase Extraction Capillary Electrophoresis Mass Spectrometry. (PubMed, J Proteome Res) - "Finally, the established method was used to analyze two rhEPO products (EPOCIM and NeuroEPO plus), demonstrating its applicability in biopharmaceutical analysis. The sensitivity of the proposed PBA-SPE-CE-MS method improves the existing CE-MS methodologies for glycopeptide analysis and shows a great potential in glycoprotein analysis to deeply characterize protein glycosites even at low concentrations of the protein digest."

Journal

A unique erythropoietin dosage induces the recovery of Long-Term synaptic Potentiation in fimbria-fornix lesioned rats. (PubMed, Brain Res) - "Restoring LTP by EPO might be a potential tool for the treatment of memory disturbing diseases like Alzheimeŕs disease. Ongoing clinical trials are evaluating a potential therapeutic effect of low sialic acid-EPO (NeuroEPO) on degenerative diseases."

Journal • Preclinical • Cognitive Disorders

The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity. (PubMed, Front Neurosci) - P1/2 | "A combined mediation model showed that 66% of the total effect of the cognitive improvement was mediated by qEEG (p = 0.0001), with the remaining direct effect between dose and Cognition (p = 0.002), due to other causes. These results suggest that Neuroepo has a positive influence on Cognition in PD patients and that a large portion of this effect is mediated by brain mechanisms reflected in qEEG."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study. (PubMed, Mov Disord) - "This study demonstrated the safety and tolerability of NeuroEPO in SCA2 patients after 6 months of treatments and suggested a small clinical effect of this drug on motor and cognitive abnormalities, but confirmatory studies are warranted."

Journal • Ataxia • CNS Disorders • Movement Disorders • Parkinson's Disease

NEUROEPO IN MILD-TO-MODERATE ALZHEIMER’S CLINICAL SYNDROME. PHASE 2-3 CONTROLLED CLINICAL TRIAL (ADPD 2022) - "Overall NeuroEPO significantly improved clinical outcomes with a good safety profile in patients with mild-to-moderate Alzheimer’s clinical syndrome."

Clinical • P2/3 data • Alzheimer's Disease • CNS Disorders • Immunology

Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis. (PubMed, J Pharm Biomed Anal) - "Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products. The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases."

Journal • CNS Disorders